HAE attacks reduced with Takeda's Takhzyro

Japan’s largest drugmaker Takeda Pharmaceutical (TYO: 4502) has announced new data from an ad-hoc analysis of the Phase III HELP Study, designed to evaluate the onset of action for Takhzyro (lanadelumab) during days 0-69 of treatment.

The analysis suggests that Takhzyro starts to prevent hereditary angioedema (HAE) attacks during this early treatment phase, with patients experiencing an 80.1% decrease in mean monthly attack rate compared to placebo. The results were presented during the European Academy of Allergy and Clinical Immunology (EAACI) Congress in Lisbon, Portugal. HAE is a rare, genetic and potentially life-threatening disorder that can result in recurrent attacks of oedema (swelling) in various parts of the body.

Takhzyro was originated by Dyax Corp before being picked up in 2016 for $5.9 billion by rare disease specialist Shire, which in turn was acquired by Takeda, in a $62 billion deal that completed earlier this year.